SCHEMBL2729919

SCHEMBL2729919

C#CC1CCC(C(=O)OC)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.37
STS P08842 1/20 0.36
RECQL P46063 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
BRD4 O60885 1/20 0.35
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4550488 0.83 UCHL1 (0.35) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL3302201 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL599498 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL3299171 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL599499 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL3240371 0.81 SMN1; SMN2 (0.41) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL14555092 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL10163242 0.81 TSHR (0.43) HSD17B10SMN1; SMN2HPGDSTSRECQL
SCHEMBL31351939 0.81 HSD17B10 (0.43) HSD17B10SMN1; SMN2HPGDRECQLPTPN2
SCHEMBL31351938 0.81 HSD17B10 (0.43) HSD17B10SMN1; SMN2HPGDRECQLPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2632469-A2 TRICYCLIC MGLUR5 RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
US-20130210804-A1 TRICYCLIC MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2013-08-15 US disclosed
US-20130210804-A1 TRICYCLIC MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2013-08-15 US disclosed
US-20130210804-A1 TRICYCLIC MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2013-08-15 US disclosed
WO-2012061019-A2 TRICYCLIC MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-05-10 WO disclosed
WO-2012061019-A2 TRICYCLIC MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210804-A1 TRICYCLIC MGLUR5 RECEPTOR MODULATORS GRM5, GRM1, GRM2 HSD17B10 1950/4885SMN1; SMN2 1501/4885HPGD 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.